Moderna & Merck announce 3-year data for mRNA-4157 in combination with Keytruda
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Merck shared updates on the company’s oncology pipeline and focused R&D approach
The cancer screening and awareness camp will run for four months in the Mira Bhayander Region, benefiting approximately 5,000 police personnel
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Greg was also central to the planning, design, and construction of this facility
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Subscribe To Our Newsletter & Stay Updated